JP2009513689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009513689A5 JP2009513689A5 JP2008538353A JP2008538353A JP2009513689A5 JP 2009513689 A5 JP2009513689 A5 JP 2009513689A5 JP 2008538353 A JP2008538353 A JP 2008538353A JP 2008538353 A JP2008538353 A JP 2008538353A JP 2009513689 A5 JP2009513689 A5 JP 2009513689A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amino acid
- sdf
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 12
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 208000012902 Nervous system disease Diseases 0.000 claims 7
- 208000025966 Neurological disease Diseases 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 201000006417 multiple sclerosis Diseases 0.000 claims 5
- 208000016192 Demyelinating disease Diseases 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 208000028389 Nerve injury Diseases 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000008764 nerve damage Effects 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000000472 traumatic effect Effects 0.000 claims 3
- 102000006573 Chemokine CXCL12 Human genes 0.000 claims 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 102000008300 Mutant Proteins Human genes 0.000 claims 2
- 108010021466 Mutant Proteins Proteins 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 102000003780 Clusterin Human genes 0.000 claims 1
- 108090000197 Clusterin Proteins 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 102000004264 Osteopontin Human genes 0.000 claims 1
- 108010081689 Osteopontin Proteins 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05110206 | 2005-10-31 | ||
| US73414205P | 2005-11-07 | 2005-11-07 | |
| PCT/EP2006/067949 WO2007051785A2 (en) | 2005-10-31 | 2006-10-30 | Use of sdf-1 for the treatment and/or prevention of neurological diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009513689A JP2009513689A (ja) | 2009-04-02 |
| JP2009513689A5 true JP2009513689A5 (enExample) | 2009-12-17 |
Family
ID=35967039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008538353A Pending JP2009513689A (ja) | 2005-10-31 | 2006-10-30 | 神経学的疾患の治療、及び／又は予防のためのｓｄｆ−１の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080253996A1 (enExample) |
| EP (1) | EP1942940A2 (enExample) |
| JP (1) | JP2009513689A (enExample) |
| KR (1) | KR20080060226A (enExample) |
| CN (1) | CN101300031A (enExample) |
| AR (1) | AR058173A1 (enExample) |
| AU (1) | AU2006310577B2 (enExample) |
| BR (1) | BRPI0617823A2 (enExample) |
| CA (1) | CA2617598A1 (enExample) |
| EA (1) | EA015716B1 (enExample) |
| NZ (1) | NZ565639A (enExample) |
| UA (1) | UA96926C2 (enExample) |
| WO (1) | WO2007051785A2 (enExample) |
| ZA (1) | ZA200800981B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7696309B2 (en) | 2006-10-23 | 2010-04-13 | The Brigham And Women's Hospital, Inc. | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| WO2011106234A1 (en) * | 2010-02-25 | 2011-09-01 | Provasculon, Inc. | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| US9249204B2 (en) * | 2011-06-01 | 2016-02-02 | Jyant Technologies, Inc. | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| JP6145089B2 (ja) * | 2011-06-07 | 2017-06-07 | メソブラスト インターナショナル エスエイアールエル | ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法 |
| US11419916B2 (en) * | 2012-09-11 | 2022-08-23 | Energesis Pharmaceuticals, Inc. | Methods and compositions for inducing differentiation of human brown adipocyte progenitors |
| US9797910B2 (en) | 2013-06-19 | 2017-10-24 | Merck Sharp & Dohme Corp. | Assay for determining endogenous levels of analyte in vivo |
| EP3191991B1 (en) * | 2014-09-10 | 2021-01-13 | Koninklijke Philips N.V. | Image report annotation identification |
| ITUA20161364A1 (it) | 2016-03-04 | 2017-09-04 | Antonino Cattaneo | Inibitore di tnf alpha astrocitario per l’uso nel trattamento di malattie neurologiche. |
| US20180222957A1 (en) * | 2017-02-03 | 2018-08-09 | Vicapsys, Inc. | Modified cxcl12 polypeptides and uses thereof |
| CN107325187B (zh) * | 2017-07-19 | 2021-11-09 | 黄子为 | 一种具有cxcr4蛋白激动活性的多肽及其应用和药物组合物 |
| US11553871B2 (en) | 2019-06-04 | 2023-01-17 | Lab NINE, Inc. | System and apparatus for non-invasive measurement of transcranial electrical signals, and method of calibrating and/or using same for various applications |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1235692A (en) | 1991-01-18 | 1992-08-27 | Synergen, Inc. | Methods for treating tumor necrosis factor mediated diseases |
| CA2117953C (en) * | 1993-10-14 | 2001-12-11 | Tasuku Honjo | Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same |
| JP2002506830A (ja) * | 1998-03-13 | 2002-03-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 治療的ケモカイン受容体アンタゴニスト |
| CA2245224A1 (en) * | 1998-08-14 | 2000-02-14 | Jiang-Hong Giong | Chemokine receptor antagonists and chemotherapeutics |
| US7157418B1 (en) * | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| DE10027383A1 (de) * | 2000-06-02 | 2001-12-20 | Rhein Biotech Proz & Prod Gmbh | Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz |
| US20040037811A1 (en) * | 2002-08-22 | 2004-02-26 | The Cleveland Clinic Foundation | Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy |
| EP1493438A1 (en) * | 2003-07-03 | 2005-01-05 | Bayer HealthCare AG | Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states |
| JP5026083B2 (ja) * | 2003-10-31 | 2012-09-12 | クロンズ ホールディングズ カンパニー リミテッド | 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法 |
-
2006
- 2006-10-30 WO PCT/EP2006/067949 patent/WO2007051785A2/en not_active Ceased
- 2006-10-30 AU AU2006310577A patent/AU2006310577B2/en not_active Ceased
- 2006-10-30 CA CA002617598A patent/CA2617598A1/en not_active Abandoned
- 2006-10-30 EP EP06807673A patent/EP1942940A2/en not_active Ceased
- 2006-10-30 KR KR1020087007031A patent/KR20080060226A/ko not_active Ceased
- 2006-10-30 ZA ZA200800981A patent/ZA200800981B/xx unknown
- 2006-10-30 BR BRPI0617823-5A patent/BRPI0617823A2/pt not_active IP Right Cessation
- 2006-10-30 UA UAA200802964A patent/UA96926C2/ru unknown
- 2006-10-30 EA EA200801244A patent/EA015716B1/ru not_active IP Right Cessation
- 2006-10-30 NZ NZ565639A patent/NZ565639A/en not_active IP Right Cessation
- 2006-10-30 JP JP2008538353A patent/JP2009513689A/ja active Pending
- 2006-10-30 CN CNA2006800404916A patent/CN101300031A/zh active Pending
- 2006-10-30 US US12/067,224 patent/US20080253996A1/en not_active Abandoned
- 2006-10-31 AR ARP060104776A patent/AR058173A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1425028B1 (en) | Use of il-18 inhibitors for the treatement or prevention of sepsis | |
| ES2690147T3 (es) | Apelina pegilada y usos de la misma | |
| JP2010518079A5 (enExample) | ||
| US20120058083A1 (en) | Therapies for Chronic Inflammatory Demyelinating Polyneuropathy Using Interferon-Beta | |
| CN103476933A (zh) | 白介素1受体的拮抗剂 | |
| JP2009513689A5 (enExample) | ||
| KR100520723B1 (ko) | 파골(破骨)세포 형성 억제제 | |
| JP2011078434A (ja) | 変異ニューブラスチンのポリマー結合体 | |
| CN100519581C (zh) | 干扰素-β复合物 | |
| US20130156694A1 (en) | Hsp70 fusion protein conjugates and uses thereof | |
| CN113956346B (zh) | 一种重组白介素-15变体 | |
| CN111788217A (zh) | 白介素-15活性的拮抗剂肽 | |
| WO2006028497A2 (en) | Active recombinant human lysozyme | |
| AU2022276188A1 (en) | Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof | |
| CN114751962A (zh) | 订书肽、其制备方法及其制药用途 | |
| EP1799248B1 (en) | Use of il-17f for the treatment and/or prevention of neurologic diseases | |
| AU2002309887B2 (en) | Use of IL-18 inhibitors for the treatment or prevention of sepsis | |
| CN101189024A (zh) | 稳定的il-21组合物 | |
| AU2002309887A1 (en) | Use of IL-18 inhibitors for the treatment or prevention of sepsis |